GREEN CLINIC & RESEARCH CENTER
Pediatric and adult infectious disease, Internal Medicine, General Pediatrics
Graduated from faculty of medicine, Alexandria University, obtained internships, trainings and degrees in pediatrics and in adult critical care medicine, worked as full-time pediatricians in Egypt and KSA. Proceed with Arab Board in KSA, published over 30 articles indexed in Medline with i10-index 17.

Presenter of 1 Presentation

DOES DIRECTLY ACTING ANTIVIRAL DRUG THERAPY FOR CHRONIC HCV INFECTION AFFECT THE REMISSION IN SURVIVORS OF CHILDHOOD MALIGNANCY?

Session Type
Oral Presentations
Date
Thu, 24.02.2022
Session Time
10:00 AM - 11:00 AM
Room
Sala A
Session Icon
Pre-Recorded with Live Q&A
Lecture Time
10:50 AM - 11:00 AM

Abstract

Background

The effects of the direct-acting antiviral drug therapy (DAA) for chronic hepatitis C on infected survivors of childhood cancer have not been well investigated in pediatric age groups.

Aims

We conducted a prospective multicenter study to investigate the effect of dual sofosbuvir/daclatasvir therapy on both the HCV clearance and state of cancer remission in survivors of childhood cancer infected with chronic HCV.

Methods

Consecutive chronic HCV-infected survivors of childhood malignancy were included in the study. All were treated with SOF/DCV for 12 weeks and were closely monitored for virus load, liver and kidney functions, and hematologic indices. Follow-up was continued for 48 weeks and included clinical examination, imaging studies, and laboratory investigations for evidence of any recurrence or de novo occurrence of malignant disease.

Results

A total of 49 chronic HCV infected pediatric patients were included; 29 survivors of malignant solid tumors, and 20 survivors of hematologic malignancies (leukemia/lymphoma). Their age ranged from 6 to 17 years (mean ± SD = 10.5 ± 3). All patients achieved SVR12 (100% ITT). No single relapse or recurrence was detected for the original malignant disease or the HCV infection. No de novo occurrence of malignancy was also observed throughout the follow-up period of 48 weeks.

Conclusions

SOF/DCV combined therapy might be used safely and effectively in the treatment of chronic HCV infected survivors of solid tumors or hematologic malignancy (leukemia/lymphoma) in pediatric age groups. No relapses were detected during treatment and throughout the follow up period for either the original malignant disease or the HCV infection.

Hide